[LDL-c and residual cardiovascular risk in patients with coronary artery disease].
Understanding how cholesterol continues driving heart disease despite treatment creates opportunities to better prevent future heart attacks and strokes.
In secondary prevention, current therapeutic management of dyslipidemia primarily aims to reduce low-density lipoprotein cholesterol (LDL-c) levels, as LDL-c is a major driver of atherosclerosis. This article aims to explore the underlying causes of and potential solutions to this therapeutic gap, which is associated with an increased risk of cardiovascular morbidity and mortality.
What the study was
- Study design
- Randomized controlled trial
- Category
- Prevention
- Maturity
- Potentially Practice-Changing
- Journal
- Ann Cardiol Angeiol (Paris)
Why it surfaced
Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 8/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.